Sub-chronic (13-week) oral toxicity study in rats with recombinant human lactoferrin produced in the milk of transgenic cows.

The oral toxicity of recombinant human lactoferrin (rhLF) produced in the milk of transgenic cows was investigated in Wistar rats by daily administration via oral gavage for 13 consecutive weeks, 7 days per week. The study used four groups of 20 rats/sex/dose. The control group received physiological saline and the three test groups received daily doses of 200, 600 and 2000 mg of rhLF per kg body weight. Clinical observations, growth, food consumption, food conversion efficiency, water consumption, neurobehavioural testing, ophthalmoscopy, haematology, clinical chemistry, renal concentration test, urinalysis, organ weights and gross examination at necropsy and microscopic examination of various organs and tissues were used as criteria for detecting the effects of treatment. Overall, no treatment-related, toxicologically significant changes were observed. The few findings that may be related to the treatment (lower cholesterol in high-dose females, lower urinary pH in high-dose males and females and very slightly higher kidney weight in high-dose females) were considered of no toxicological significance. Based on the absence of treatment-related, toxicologically relevant changes, the no-observed-adverse-effect level (NOAEL) was considered to be at least 2000 mg/kg body weight/day.

[1]  R. Brines,et al.  The effect of trypsin and chymotrypsin on the in vitro antimicrobial and iron-binding properties of lactoferrin in human milk and bovine colostrum. Unusual resistance of human apolactoferrin to proteolytic digestion. , 1983, Biochimica et biophysica acta.

[2]  K. Rasmussen,et al.  A low-fat diet but not food restriction improves lactational performance in obese rats. , 2001, Advances in experimental medicine and biology.

[3]  B. Lönnerdal,et al.  Cellular internalization of lactoferrin in intestinal epithelial cells , 2004, Biometals.

[4]  E. Pauwels,et al.  Large scale production of recombinant human lactoferrin in the milk of transgenic cows , 2002, Nature Biotechnology.

[5]  R. Ellison,et al.  Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin , 1988, Infection and immunity.

[6]  P. V. Berkel,et al.  Structure and biological actions of lactoferrin , 1996, Journal of Mammary Gland Biology and Neoplasia.

[7]  J. Brock,et al.  Inhibition of Escherichia coli by bovine colostrum and post-colostral milk. II. The bacteriostatic effect of lactoferrin on a serum susceptible and serum resistant strain of E. coli. , 1975, Immunology.

[8]  M. Harmsen,et al.  Antiviral activities of lactoferrin. , 2001, Antiviral research.

[9]  B. Nichols,et al.  Human Lactoferrin Stimulates Thymidine Incorporation into DNA of Rat Crypt Cells , 1987, Pediatric Research.

[10]  M. Neville,et al.  Human lactoferrin in the milk of transgenic mice increases intestinal growth in ten-day-old suckling neonates. , 2001, Advances in experimental medicine and biology.

[11]  H. Broxmeyer,et al.  Lactoferrin decreases monocyte-induced fibroblast production of myeloid colony-stimulating activity by suppressing monocyte release of interleukin-1. , 1989, Blood.

[12]  R. Ellison,et al.  Killing of gram-negative bacteria by lactoferrin and lysozyme. , 1991, The Journal of clinical investigation.

[13]  P. V. van Berkel,et al.  The role of N-linked glycosylation in the protection of human and bovine lactoferrin against tryptic proteolysis. , 2004, European journal of biochemistry.

[14]  T. V. van Berkel,et al.  Removal of 14 N-terminal amino acids of lactoferrin enhances its affinity for parenchymal liver cells and potentiates the inhibition of beta- very low density lipoprotein binding. , 1993, The Journal of biological chemistry.

[15]  A. Kijlstra,et al.  Modulation of classical C3 convertase of complement by tear lactoferrin. , 1982, Immunology.

[16]  D. Rice,et al.  Structure of human lactoferrin: crystallographic structure analysis and refinement at 2.8 A resolution. , 1989, Journal of molecular biology.

[17]  Miguel Calvo Rebollar,et al.  Biological role of lactoferrin. , 1992, Archives of disease in childhood.

[18]  H. Tilson,et al.  The IPCS Collaborative Study on Neurobehavioral Screening Methods: II. Protocol design and testing procedures. , 1997, Neurotoxicology.

[19]  B. Appelmelk,et al.  Lactoferrin is a lipid A-binding protein , 1994, Infection and immunity.

[20]  P. Furmanski,et al.  Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA , 1995, Nature.

[21]  K. Yamauchi,et al.  13-Week oral repeated administration toxicity study of bovine lactoferrin in rats. , 2000, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[22]  Wangkun Lee,et al.  The Protective Effects of Lactoferrin Feeding against Endotoxin Lethal Shock in Germfree Piglets , 1998, Infection and Immunity.

[23]  B. Petschow,et al.  Response of Bifidobacterium Species to Growth Promoters in Human and Cow Milk , 1991, Pediatric Research.

[24]  J. Abrahams,et al.  The protein structure of recombinant human lactoferrin produced in the milk of transgenic cows closely matches the structure of human milk-derived lactoferrin , 2005, Transgenic Research.

[25]  D. Mann,et al.  Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. , 1994, The Journal of biological chemistry.

[26]  V. Salmon,et al.  The N-terminal Arg2, Arg3 and Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T-cells. , 1997, The Biochemical journal.

[27]  M. Tomita,et al.  Antimicrobial peptides of lactoferrin. , 1994, Advances in experimental medicine and biology.